COVID-19-associated neuropsychiatric complications are soaring. There is an urgent need to understand the link between COVID-19 and neuropsychiatric disorders. To that end, this article addresses the premise that SARS-CoV-2 infection results in gut dysbiosis and an altered microbiota-gut-brain (MGB) axis that in turn contributes to the neuropsychiatric ramifications of COVID-19. Altered MGB axis activity has been implicated independently as a risk of neuropsychiatric disorders. A review of the changes in gut microbiota composition in individual psychiatric and neurological disorders and gut microbiota in COVID-19 patients revealed a shared “microbial signature” characterized by a lower microbial diversity and richness and a decrease in health-promoting anti-inflammatory commensal bacteria accompanied by an increase in opportunistic proinflammatory pathogens. Notably, there was a decrease in short-chain fatty acid (SCFA) producing bacteria. SCFAs are key bioactive microbial metabolites with anti-inflammatory functions and have been recognized as a critical signaling pathway in the MGB axis. SCFA deficiency is associated with brain inflammation, considered a cardinal feature of neuropsychiatric disorders. The link between SARS-CoV-2 infection, gut dysbiosis, and altered MGB axis is further supported by COVID-19-associated gastrointestinal symptoms, a high number of SARS-CoV-2 receptors, angiotensin-cleaving enzyme-2 (ACE-2) in the gut, and viral presence in the fecal matter. The binding of SARS-CoV-2 to the receptor results in ACE-2 deficiency that leads to decreased transport of vital dietary components, gut dysbiosis, proinflammatory gut status, increased permeability of the gut-blood barrier (GBB), and systemic inflammation. More clinical research is needed to substantiate further the linkages described above and evaluate the potential significance of gut microbiota as a diagnostic tool. Meanwhile, it is prudent to propose changes in dietary recommendations in favor of a high fiber diet or supplementation with SCFAs or probiotics to prevent or alleviate the neuropsychiatric ramifications of COVID-19.
【초록키워드】 COVID-19, SARS-CoV-2, Inflammation, Anti-inflammatory, SARS-COV-2 infection, diagnostic, risk, Brain, ACE-2, proinflammatory, Research, Complication, Neuropsychiatric, Pathogens, Bacteria, gut microbiota, systemic inflammation, signaling pathway, receptor, Critical, metabolite, binding, gastrointestinal symptoms, Neurological disorder, COVID-19 patient, fecal, Gut, microbial, Transport, deficiency, Psychiatric, commensal bacteria, disorders, components, favor, viral presence, SARS-CoV-2 receptors, gut microbiota composition, anti-inflammatory function, recommendation, fiber, Prevent, decrease, described, evaluate, supported, characterized, changes in, contribute, increase in, producing, implicated, turn, alleviate, accompanied, Altered, fatty, SCFA, 【제목키워드】 acid, disturbance, axis, ramification,